These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 25682771)
1. MicroRNAs in renal cell carcinoma: a systematic review of clinical implications (Review). Li M; Wang Y; Song Y; Bu R; Yin B; Fei X; Guo Q; Wu B Oncol Rep; 2015 Apr; 33(4):1571-8. PubMed ID: 25682771 [TBL] [Abstract][Full Text] [Related]
2. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review. Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391 [TBL] [Abstract][Full Text] [Related]
3. Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways. Lichner Z; Mejia-Guerrero S; Ignacak M; Krizova A; Bao TT; Girgis AH; Youssef YM; Yousef GM Am J Pathol; 2012 Apr; 180(4):1675-87. PubMed ID: 22326755 [TBL] [Abstract][Full Text] [Related]
4. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299 [TBL] [Abstract][Full Text] [Related]
5. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor. Shang D; Liu Y; Yang P; Chen Y; Tian Y Urology; 2012 Apr; 79(4):966.e1-7. PubMed ID: 22341602 [TBL] [Abstract][Full Text] [Related]
6. The complex roles of microRNAs in the metastasis of renal cell carcinoma. Zhang L; Xul B; Chen S; Lu K; Liu C; Wang Y; Zhao Y; Zhang X; Liu D; Chen M J Nanosci Nanotechnol; 2013 May; 13(5):3195-203. PubMed ID: 23858831 [TBL] [Abstract][Full Text] [Related]
7. MicroRNAs in the pathogenesis of renal cell carcinoma and their diagnostic and prognostic utility as cancer biomarkers. Fedorko M; Pacik D; Wasserbauer R; Juracek J; Varga G; Ghazal M; Nussir MI Int J Biol Markers; 2016 Feb; 31(1):e26-37. PubMed ID: 26481440 [TBL] [Abstract][Full Text] [Related]
8. Renal cell carcinoma development and miRNAs: a possible link to the EGFR pathway. Dias F; Teixeira AL; Santos JI; Gomes M; Nogueira A; Assis J; Medeiros R Pharmacogenomics; 2013 Nov; 14(14):1793-803. PubMed ID: 24192126 [TBL] [Abstract][Full Text] [Related]
9. MicroRNAs: exploring a new dimension in the pathogenesis of kidney cancer. White NM; Yousef GM BMC Med; 2010 Oct; 8():65. PubMed ID: 20964839 [TBL] [Abstract][Full Text] [Related]
10. MicroRNAs in Renal Cell Carcinoma. Sellitti DF; Doi SQ Microrna; 2015; 4(1):26-35. PubMed ID: 26165467 [TBL] [Abstract][Full Text] [Related]
11. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. Yao M; Tabuchi H; Nagashima Y; Baba M; Nakaigawa N; Ishiguro H; Hamada K; Inayama Y; Kishida T; Hattori K; Yamada-Okabe H; Kubota Y J Pathol; 2005 Feb; 205(3):377-87. PubMed ID: 15682440 [TBL] [Abstract][Full Text] [Related]
13. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Pantuck AJ; Zeng G; Belldegrun AS; Figlin RA Clin Cancer Res; 2003 Oct; 9(13):4641-52. PubMed ID: 14581333 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study. Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SY; Roche-Losada O; Sánchez-Prieto R; Giménez-Bachs JM Clin Genitourin Cancer; 2017 Dec; 15(6):e923-e933. PubMed ID: 28624320 [TBL] [Abstract][Full Text] [Related]
15. The role of natural products versus miRNA in renal cell carcinoma: implications for disease mechanisms and diagnostic markers. Ayed A Naunyn Schmiedebergs Arch Pharmacol; 2024 Sep; 397(9):6417-6437. PubMed ID: 38691151 [TBL] [Abstract][Full Text] [Related]
16. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750 [TBL] [Abstract][Full Text] [Related]
17. HIFing the brakes: therapeutic opportunities for treatment of human malignancies. Garcia JA Sci STKE; 2006 May; 2006(337):pe25. PubMed ID: 16738063 [TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNAs in renal cell carcinoma: A systematic review and clinical implications. Li M; Wang Y; Cheng L; Niu W; Zhao G; Raju JK; Huo J; Wu B; Yin B; Song Y; Bu R Oncotarget; 2017 Jul; 8(29):48424-48435. PubMed ID: 28467794 [TBL] [Abstract][Full Text] [Related]
19. The emerging role of nuclear factor kappa B in renal cell carcinoma. Morais C; Gobe G; Johnson DW; Healy H Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869 [TBL] [Abstract][Full Text] [Related]
20. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Blancher C; Moore JW; Robertson N; Harris AL Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]